Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer
نویسندگان
چکیده
منابع مشابه
Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Results from multiple clinical trials involving aromatase inhibitors have added to the knowledge base relating to endocrine therapy of postmenopausal women with hormone receptor-positive early breast cancer. In the extended adjuvant setting, data from the Austrian Breast and Colorectal Cancer Study Group 6a trial showed an advantage for anastrozole following 5 years of tamoxifen treatment, cons...
متن کاملAdjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer
From the Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Coordinating Center, Bern; Oncology Institute of Southern Switzerland, Bellinzona & Lugano, Switzerland; International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute...
متن کاملScheduling the adjuvant endocrine therapy for early stage breast cancer
Based on the data available through published trial results, we build a mixed integer nonlinear programming (MINLP) model in order to find an optimal treatment plan for a given HR+ early stage breast cancer patient who is postmenopausal. The objective is to maximize the disease-free survival percentage at the end of the treatment period subject to the constraints on the risk of contralateral br...
متن کاملSelecting adjuvant endocrine therapy for breast cancer.
This year alone, more than 215,000 women in the United States will be diagnosed with, and over 40,000 will die from, invasive breast cancer. Recently, mortality from female breast cancer has declined despite an increase in its incidence. This decline corresponds with improved screening for prompt tumor detection, and advances in the treatment of early disease. Of these, endocrine therapy has pl...
متن کاملAdjuvant endocrine therapy for breast cancer.
Endocrine therapy is a critical part of adjuvant therapy in women with hormone receptor-positive breast cancer, and has been shown to reduce the risk of recurrence and death from breast cancer. For decades, 5 years of tamoxifen has been the standard treatment. For premenopausal women, it remains so, and we await the results of ongoing trials to define the role of ovarian suppression or ablation...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Future Oncology
سال: 2017
ISSN: 1479-6694,1744-8301
DOI: 10.2217/fon-2017-0427